


Name	Hidenori Kage	
Country	Japan	
Organization	The University of Tokyo	
Current Position	Professor	

Educational Background

School of Medicine, The University of Tokyo	2000	M.D.
Graduate School of Medicine, the University of Tokyo	2008	Ph.D.

Professional Experiences

The University of Tokyo Hospital	6/00 – 5/01	Resident, Internal Medicine
Japanese Red Cross Medical Center	6/01 – 5/02	Resident, Internal Medicine
Kanto Medical Center, NTT EC	6/02 – 5/04	Fellow, Pulmonary Medicine
The University of Tokyo Hospital	4/08 – 5/09	Fellow, Department of Clinical Laboratory
The University of Tokyo Hospital	6/09 – 6/11	Assistant Professor Department of Respiratory Medicine
University of Southern California	8/11 – 6/14	Postdoctoral Research Associate,
The University of Tokyo Hospital	8/14 – 4/16	Assistant Professor
The University of Tokyo Hospital	4/16 – 3/21	Lecturer Department of Respiratory Medicine
The University of Tokyo Hospital	4/21 – 10/23	Associate Professor Next-Generation Precision Medicine Development Laboratory
The University of Tokyo Hospital Medicine	11/23 – present	Professor, Department of Respiratory

Professional Organizations

The Japanese Society of Internal Medicine
 The Japanese Respiratory Society
 American Thoracic Society
 Japanese Cancer Association
 Japanese Society of Medical Oncology
 American Association for Cancer Research
 The Japan Lung Cancer Society

Main Scientific Publications

Publications from the last 3 years:

1. Kage H, Oda K, Muto M, Tsuchihara K, Okita N, Okuma Y, Kikuchi J, Shiota H, Hayashi H, Kokuryo T, Sakai D, Hirasawa A, Kubo M, Kenmotsu H, Akiyama N, Shinozaki-Ushiku A, Tanabe M, Ushiku T, Miyagawa K, Seto Y. Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan. *Cancer Sci* 2023 Online ahead of print.
2. Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K. Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial. *Cancer Sci* 2023 Online ahead of print.
3. Kage H, Shinozaki-Ushiku A, Ishigaki K, Sato Y, Tanabe M, Tanaka S, Tanikawa M, Watanabe K, Kato S, Akagi K, Uchino K, Mitani K, Takahashi S, Miura Y, Ikeda S, Kojima Y, Watanabe K, Mochizuki H, Yamaguchi H, Kawazoe Y, Kashiwabara K, Kohsaka S, Tatsuno K, Ushiku T, Ohe K, Yatomi Y, Seto Y, Aburatani H, Mano H, Miyagawa K, Oda K. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan. *Cancer Sci* 2023;114:1710-1717
4. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shiota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. *JAMA Netw Open* 2022;5:e2245081.
5. Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S. High-throughput functional evaluation of MAP2K1 variants in cancer. *Mol Cancer Ther*. 2022 (Online ahead of print)
6. Matsumoto Y, Kage H, Morota M, Zokumasu K, Ando T, Maemura K, Watanabe K, Kawakami M, Hinata M, Ushiku T, Nakajima J, Nagase T. Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer. *Jpn J Clin Oncol*. 2023;53:63-73.
7. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, Yoshino T. Chronological improvement in precision oncology implementation in Japan. *Cancer Sci*. 2022;113:3995-4000.
8. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M, Kohsaka S, Tsuchihara K, Naito Y, Yoshino T. Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors. *Cancer Sci*. 2022;113:3646-3656
9. Amano Y, Kage H, Tanaka G, Sato Y, Tanaka M, Nagase T. Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report. *Case Rep Oncol* 2022;15:338-344.
10. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K. Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol* 2022;52:917-921.
11. Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K. Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells. *Inflammation* 2022;45:1765-1779.
12. Miyamoto S, Yamazaki T, Shimizu K, Matsubara T, Kage H, Watanabe K, Kobo H, Matsuyama Y, Rodin G, Yoshiuchi K. Brief, manualised and semistructured individual psychotherapy

- programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. *BMJ Open* 2022;12:e056136.
13. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T. Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep* 2022;3:100277.
 14. Ikushima H, Hiraishi Y, Toriumi K, Ando T, Tamiya H, Ishida J, Amano Y, Kage H, Tanaka G, Nagase T. Multiple cerebral infarctions in ROS1-rearranged lung adenocarcinoma. *Respirol Case Rep* 2021;9:e0831.
 15. Kurokawa R, Inui S, Gonoï W, Nakai Y, Ishida M, Watanabe Y, Kubo T, Amano Y, Okamoto K, Kage H, Harada S, Tanaka G, Kawahara T, Nagase T, Moriya K, Abe O. Standardized reporting systems of chest computed tomography in a population with low coronavirus disease 2019 prevalence: A retrospective comparative study. *Heliyon* 2021;7:e07743.
 16. Ando T, Kage H, Matsumoto Y, Zokumasu K, Nagase T. Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease. *Respir Investig* 2021;59:777-782.
 17. Manaka K, Sato J, Takeuchi M, Watanabe K, Kage H, Kawai T, Sato Y, Miyagawa T, Yamada D, Kume H, Sato S, Nagase T, Iiri T, Nangaku M, Makita N. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. *Sci Rep* 2021;11:11617.
 18. Amano Y, Kage H, Tanaka G, Gonoï W, Nakai Y, Kurokawa R, Inui S, Okamoto K, Harada S, Iwabu M, Morizaki Y, Abe O, Moriya K, Nagase T. Diagnostic prediction of COVID-19 based on clinical and radiological findings in a relatively low COVID-19 prevalence area. *Respir Investig* 2021;59:446-453.
 19. Sunami K, Naito Y, Aïmono E, Amano T, Ennishi D, Kage H, Kanai M, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Yoshino T. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. *Int J Clin Oncol* 2021;26:443-449.
 20. Horie M, Castaldi A, Sunohara M, Wang H, Ji Y, Liu Y, Li F, Wilkinson TA, Hung L, Shen H, Kage H, Offringa IA, Marconett CN, Flodby P, Zhou B, Borok Z. Integrated Single-Cell RNA-Sequencing Analysis of Aquaporin 5-Expressing Mouse Lung Epithelial Cells Identifies GPRC5A as a Novel Validated Type I Cell Surface Marker. *Cells* 2020;9:E2460.
 21. Yotsumoto T, Maemura K, Watanabe K, Amano Y, Matsumoto Y, Zokumasu K, Ando T, Kawakami M, Kage H, Nakajima J, Yatomi Y, Nagase T, Takai D. NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. *Oncotarget* 2020;11:3590-3600.
 22. Ando T, Kawashima M, Jo T, Masuda K, Yamauchi Y, Tanaka G, Kage H, Suzukawa M, Nagai H, Matsui H, Fushimi K, Yasunaga H, Nagase T. Early Arterial Embolization and Mortality in Mechanically Ventilated Patients with Hemoptysis: A Nationwide Retrospective Cohort Study. *Crit Care Med* 2020;48:1480-1486.
 23. Watanabe K, Kage H, Nagoshi S, Toyama K, Ohno Y, Shinozaki-Ushiku A, Nakazaki K, Suzuki H, Kurokawa M, Nagase T. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. *Case Rep Oncol Med* 2020 19;2020:4201727
 24. Shinozaki-Ushiku A, Kohsaka S, Kage H, Oda K, Miyagawa K, Nakajima J, Aburatani H, Mano H, Ushiku T. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant. *Pathol Int* 2020;70:775-780.
 25. Ando T, Kage H, Matsumoto Y, Zokumasu K, Yotsumoto T, Maemura K, Amano Y, Watanabe K, Nakajima J, Nagase T, Takai D. Integrin α 11 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence. *Cancer Sci* 2020;111:200-208